The recently published INDIGO trial, demonstrating the benefit of the mutant IDH inhibitor vorasidenib in patients with low-grade IDH-mutant gliomas, introduces a new era of precision medicine in brain tumors that is poised to change standard-of-care. In this review, we highlight and ...
Cloughesy’s Insights on the FDA Approval of Vorasidenib in IDH-Mutant Gliomas New Method Unlocks Treatment for Melanoma's Brain Invasion Study Shows First Evidence of Effective Systemic Therapy for HER2+ Breast Cancer With LM Brain Benefits: Targeted Therapy Offers New Weapon Against HER2+ Breast...
Here we define myeloid cellular states in gliomas by longitudinal single-cell profiling and demonstrate their strict control by the tumor genotype: in isocitrate dehydrogenase (IDH)-mutant tumors, differentiation of infiltrating myeloid cells is blocked, resulting in an immature phenotype. In late-stage...
皮质脑电图和导航经颅磁刺激定制的上切除术治疗癫痫源性低度胶质瘤 The authors evaluated electrocorticography and navigated transcranial magnetic stimulation-tailored supratotal resection (ETT-SpTR) for low-grade gliomas (LGGs) in controlling seizures and preserving neurological function. Their key finding ...
Low-grade gliomas (LGG) comprise pilocytic astrocytomas, categorized as grade 1, and astrocytomas characterized by the presence of an IDH mutation, classified as grade 2. High-grade gliomas (HGG), on the other hand, consist of astrocytomas with an IDH mutation, designated as grade 3 and 4...
Isocitrate dehydrogenase (IDH) mutants define a class of gliomas that are initially slow-growing but inevitably progress to fatal disease. To characterize their malignant cell hierarchy, we profiled chromatin accessibility and gene expression across single cells from low-grade and high-grade IDH-mutant...
The FDA approved vorasidenib opens in a new tab or window(Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor -- is the first systemic therapy approved for this patient pop...
二、分子特征在胶质瘤的分类分型中扮演者越来越重要的角色,该文章是依据2016年WHO中枢神经系统肿瘤的分级进行研究的,在 2016 年 CNS WHO 分类中,胶质瘤根据组织学和分子特征进一步分类,lower-grade gliomas(LGG), isocitrate dehydrogenase-mutant (IDH-mutant) and 1p/19q-codeleted; LGG, IDH-mutant without 1p...
IDH-mutant gliomas comprise <10% of HGG in children. RRD-HGG comprise 5-10% of childhood HGG, demonstrate high mutation burden (TMB) and respond to immune-checkpoint inhibition (ICI). The impact of RRD with childhoodIDH-mutant gliomas, and effective therapeutic options for these patients are ...
If approved, vorasidenib would become a first-in-class targeted therapy for patients with IDH-mutant gliomas and would mark Servier's sixth approval across IDH-mutant cancers. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of...